Table 3 Pharmacokinetic parameters of fructose-based 3-acetyl-2,3-dihydro-1,3,4-oxadiazole (GLB) and its two metabolites M1 and M2 after a single oral administration of GLB (100 mg/kg) in rats (Mean ± SD, n = 6).

From: Quantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS

Pharmacokinetic parameters

Unit

GLB

M1

M2

Cmax

mg/L

2.78 ± 0.89

0.54 ± 0.10*

1.56 ± 0.27*

Tmax

h

6 ± 0

7.33 ± 2.73*

8.67 ± 2.73*

AUC(0-96)

mg/L·h

33.30 ± 9.10

9.66 ± 3.38*

24.56 ± 6.83

AUC(0-∞)

mg/L·h

33.49 ± 9.05

10.05 ± 3.34*

24.68 ± 6.85

t1/2

h

9.24 ± 4.74

11.30 ± 5.94

6.82 ± 2.63

  1. Compared with GLB parent drug group, *p < 0.05.
Back to article page